whatshot

ALNY   $274.24  -0.80% Market Open

Alnylam Pharmaceuticals Inc
show_chart Advanced Chart of ALNY
Last Events:

2023-09-14 The hottest instrument.

2023-08-09 Trend pattern changed from восходящий треугольник to канал.

2023-08-09 Trend Power changed from almost flat to slow.

2023-08-06 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from medium strength to almost flat.

2023-08-05 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from slow to medium strength.

Current temperature: 14.66
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 312.36
High with % probability:
Analyst Recommendations:
Number of estimates 24
Target Price Mean 286.65
Mean unverified/preliminary 286.65 / 286.65
Target Price Low / High 160.50 / 400.00
Median / STD DEV 295.50 / 58.31
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd None None None
stoch None None None
ma20 Sell Sell None
ma50 None None None
ma100 Sell Sell Sell
Candlestick PatternSept. 19, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US02043Q1076
ceo Dr. Yvonne L. Greenstreet M.B.A., MBChB
Website https://www.alnylam.com
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.